Sec Form 13G Filing - Privium Fund Management B.V. @ ProQR Therapeutics N.V.

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ProQR Therapeutics N.V.

(Name of Issuer)

Ordinary Shares, nominal value EUR0.04 per share

(Title of Class of Securities)

N71542109

(CUSIP Number)

12/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

N71542109

Names of Reporting Persons

STICHTING AESCAP LIFE SCIENCES

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,156,878.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,156,878.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,156,878.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.9 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.

SCHEDULE 13G

CUSIP No.

N71542109

Names of Reporting Persons

PRIVIUM FUND MANAGEMENT B.V.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,467,149.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,467,149.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

5,467,149.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

N71542109

Names of Reporting Persons

STICHTING AESCAP GENETICS

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,310,271.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,310,271.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,310,271.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

1.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

N71542109

Names of Reporting Persons

INSPIRATIONAL VISIONS B.V.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 35,411.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 35,411.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

35,411.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

0.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

N71542109

Names of Reporting Persons

PATRICK JOHAN HENDRIK KROL

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,528,862.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,528,862.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

5,528,862.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

ProQR Therapeutics N.V.

(b)

Address of issuer's principal executive offices:

Zernikedreef 9 Leiden, The Netherlands, CK 2333

Item 2.

(a)

Name of person filing:

(i) Stichting Aescap Life Sciences ("Aescap Life Sciences") (ii) Privium Fund Management B.V. ("Privium"), as the fund manager of Aescap Life Sciences (iii) Stichting Aescap Genetics ("Aescap Genetics") (iv) Inspirational Visions BV ("Inspirational Visions") (v) Patrick Johan Hendrik Krol ("Krol"), the portfolio manager for Privium regarding Aescap Life Sciences and Aescap Genetics and the managing director of Inspirational Visions The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

(b)

Address or principal business office or, if none, residence:

The principal business address of each of Aescap Life Sciences, Privium, Aescap Genetics and Krol is: Gustav Mahlerplein 3 1082 MS Amsterdam The Netherlands The principal business address of Inspirational Visions is: A.J. Ernststraat 595-C 1082 LN Amsterdam The Netherlands

(c)

Citizenship:

The citizenship of each of the Reporting Persons is the Netherlands.

(d)

Title of class of securities:

Ordinary Shares, nominal value EUR0.04 per share

(e)

CUSIP No.:

N71542109

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed to beneficially own the Shares held by Aescap Life Sciences and Aescap Genetics. In addition, as the managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by Inspirational Visions. As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares. As of the date of this report, Aescap Genetics directly held 1,310,271 Shares. As of the date of this report, Inspirational Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares.

(b)

Percent of class:

Aescap Life Sciences may be deemed the beneficial owner of approximately 3.9% of the Shares outstanding. Privium may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding. Aescap Genetics may be deemed the beneficial owner of approximately 1.2% of the Shares outstanding. Inspirational Visions may be deemed the beneficial owner of approximately 0.1% of the Shares outstanding. Krol may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Aescap Life Sciences: 4,156,878 Privium: 5,467,149 Aescap Genetics: 1,310,271 Inspirational Visions: 35,411 Krol: 5,528,862

(ii) Shared power to vote or to direct the vote:

Aescap Life Sciences: 0 Privium: 0 Aescap Genetics: 0 Inspirational Visions: 0 Krol: 0

(iii) Sole power to dispose or to direct the disposition of:

Aescap Life Sciences: 4,156,878 Privium: 5,467,149 Aescap Genetics: 1,310,271 Inspirational Visions: 35,411 Krol: 5,528,862

(iv) Shared power to dispose or to direct the disposition of:

Aescap Life Sciences: 0 Privium: 0 Aescap Genetics: 0 Inspirational Visions: 0 Krol: 0

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STICHTING AESCAP LIFE SCIENCES

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager
Date:	01/20/2026

PRIVIUM FUND MANAGEMENT B.V.

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Portfolio Manager
Date:	01/20/2026

STICHTING AESCAP GENETICS

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager
Date:	01/20/2026

INSPIRATIONAL VISIONS B.V.

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Managing Director
Date:	01/20/2026

PATRICK JOHAN HENDRIK KROL

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol
Date:	01/20/2026

Exhibit Information

Exhibit 99.1: Joint Filing Agreement (filed herewith).

primary_doc.xml

Sec Form 13G Filing - Privium Fund Management B.V. filing for - 2026-01-20